PANOPTES PHARMA
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria. The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatmen... t is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications. Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development.
PANOPTES PHARMA
Social Links:
Industry:
Biotechnology Health Care
Founded:
2013-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.panoptes-pharma.com
Total Employee:
1+
Status:
Active
Contact:
43 676 644 7510
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Euro IPv6 1and1
Founder
Investors List
aws Gründerfonds (aws Founders Fund)
aws Gründerfonds (aws Founders Fund) investment in Seed Round - Panoptes Pharma
4SC
4SC investment in Seed Round - Panoptes Pharma
Arax Capital Partners
Arax Capital Partners investment in Seed Round - Panoptes Pharma
Official Site Inspections
http://www.panoptes-pharma.com
- Host name: 172.67.183.242
- IP address: 172.67.183.242
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Panoptes Pharma"
Panoptes Pharma - Crunchbase Company Profile & Funding
Panoptes is a privately held biotech company focused on developing small molecule based …See details»
Unternehmen - PANOPTES PHARMA
Über Panoptes Panoptes ist ein privates Biotech-Unternehmen in der klinischen Phase, das …See details»
Panoptes Pharma - Innovationen in Ophthalmologie und Medizin
Panoptes Pharma ist ein internationales Biotechnologieunternehmen, das fortschrittliche …See details»
Über uns - PANOPTES PHARMA
Panoptes ist ein privates Biotech-Unternehmen in der klinischen Phase, das sich auf die …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Jul 3, 2023 The privately held biotech company Panoptes Pharma GmbH was founded by Dr. …See details»
Panoptes Pharma GmbH - Drug pipelines, Patents, Clinical trials
Explore Panoptes Pharma GmbH with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 7 news, and 3 literature, Disease Domain:Immune System Diseases, Nervous System Diseases, Technology Platform:Small molecule drug, Chemical drugs, Drug:KIO-201, KIO-101, PP-001.See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 The privately held biotech company Panoptes Pharma GmbH was founded by …See details»
Panoptes Pharma GmbH: Contact Details and Business Profile
Panoptes Pharma is a clinical stage biotech company focused on developing small molecule …See details»
Panoptes Pharma - Company Profile - Tracxn
Nov 17, 2024 Panoptes Pharma ranks 92nd among 201 active competitors. 69 of its …See details»
Panoptes Pharma - VentureRadar
Panoptes intends to develop PaniJect and PaniDrop up to proof-of-concept studies in different …See details»
Detail - LISA: Advancing Austrian life science
Dec 21, 2020 The privately held biotech company Panoptes Pharma GmbH was founded by …See details»
Panoptes Pharma - Funding, Financials, Valuation & Investors
Nov 2, 2015 Seed Round - Panoptes Pharma . 3: obfuscated. obfuscated. Arax Capital Partners: Investors. Edit Investors Section. Number of Lead Investors 1. Number of Investors 3. Panoptes Pharma is funded by 3 investors. aws Gründungsfonds and 4SC are the most recent investors. Which investors participated in the most funding rounds?See details»
EyeGate Pharma Announces Acquisition of Panoptes Pharma
Dec 21, 2020 EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a …See details»
Panoptes Pharma - PitchBook
Panoptes Pharma General Information Description. Provider of molecule-based therapies …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in …See details»
Panoptes Pharma DMF, CEP, Written Confirmations, FDF
Panoptes is a privately held clinical stage biotech company focused on developing small …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 --EyeGate Pharmaceuticals, Inc., a clinical stage company focused on …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 The privately held biotech company Panoptes Pharma GmbH was founded by …See details»
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma ...
The privately held biotech company Panoptes Pharma GmbH was founded by Dr. Franz Obermayr and Dr. Stefan Sperl and is located in Vienna, Austria. The highly experienced team of Panoptes has successfully developed PP-001 a third generation nanomolar inhibitor of DHODH as an intravitreal, eye drop and intravenous formulation for a wide area of indications in …See details»